Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally.
Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption.
The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden and it is listed on the Stockholm OMX Nordic Exchange.
Biovitrum is currently promoting proprietary products internationally, i.e. in Europe, North America, Australia and New Zealand, and a portfolio of prescription specialist products in the Nordic countries in collaboration with Pfizer, Amgen and other selected pharmaceutical and biotechnology companies.
Going forward, we intend to commercialize additional partnered products as well as products developed from our own project portfolio.
We develop protein pharmaceuticals for specialist care all the way to launching, marketing and sales through our own organization.
Our operations are based on extensive experience in research and pharmaceutical development. Several of Biovitrum’s scientists were pioneers in biotechnology and protein drug process development.
We have in-house research operations including cutting-edge expertise in the fields of hematology, autoimmune diseases/inflammation and malabsorption related to specialist care. The influx of new projects from our own research is complemented by strategic acquisitions, partnerships and alliances. Our project portfolio includes several projects in late clinical phases.
We are looking for collaboration opportunities in specialist pharmaceuticals.
We are looking for drugs in specialist care for in-licensing. We offer comprehensive expertise from contact with authorities, clinical trials, brand development and medical marketing.
Biopharmaceuticals have profound expertise in protein therapeutic development, from cell line development through formulation design to manufacturing for preclinical, clinical and commercial supply. Our operations are based on strong commitment, scientific credibility and exceptional regulatory experience (e.g. EMEA, FDA). Our current partners are active in Europe and the US. Biovitrum is the sole global manufacturer of the active substance in Pfizer's ReFacto AF®, a protein used for treatment of hemophilia.
We encourage an environment where good ideas and engagement are rewarded and have built an organization where decision-making paths are short. Our success is based on the dynamics of this culture and the partnerships we establish.
We are always open to discussions on innovative ideas and are keen to establish alliances with others to develop new pharmaceuticals that can give people a better life and thus generate lasting value.
